Which has preferable earnings & valuation, CMMB or TVGN?

Tevogen Bio is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A Tevogen Bio N/A N/A -$26.27M -$4.61 N/A

Is CMMB or TVGN more profitable?

Tevogen Bio's return on equity of 0.00% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -89.03% -79.68% Tevogen Bio N/A N/A -472.77%

Which has stronger earnings & valuation, CMMB or ESLA?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A

Is CMMB or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -89.03% -79.68% Estrella Immunopharma N/A N/A -397.36%

Chemomab Therapeutics (CMMB) Competitors

$2.27 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$2.32 +0.05 (+2.20%)

As of 07/2/2026 07:58 PM Eastern

Compare

CMMB vs. ELUT, TVGN, RNXT, ESLA, and BTAI

Should you buy Chemomab Therapeutics stock or one of its competitors? MarketBeat compares Chemomab Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Chemomab Therapeutics include Elutia (ELUT), Tevogen Bio (TVGN), RenovoRx (RNXT), Estrella Immunopharma (ESLA), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical products" industry.

How does Chemomab Therapeutics compare to Elutia?

Chemomab Therapeutics (NASDAQ:CMMB) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Chemomab Therapeutics currently has a consensus price target of $25.00, indicating a potential upside of 1,001.32%. Elutia has a consensus price target of $6.00, indicating a potential upside of 543.78%. Given Chemomab Therapeutics' higher probable upside, equities analysts plainly believe Chemomab Therapeutics is more favorable than Elutia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Chemomab Therapeutics has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Elutia has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

Elutia has a net margin of 312.09% compared to Chemomab Therapeutics' net margin of 0.00%. Elutia's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
Elutia	312.09%	N/A	-53.97%

Elutia has higher revenue and earnings than Chemomab Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
Elutia	$12.46M	3.20	$53.38M	$0.86	1.08

46.1% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by company insiders. Comparatively, 27.6% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Chemomab Therapeutics' average media sentiment score of 0.71 beat Elutia's score of 0.00 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Chemomab Therapeutics	Positive
Elutia	Neutral

Summary

Elutia beats Chemomab Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Tevogen Bio?

Chemomab Therapeutics (NASDAQ:CMMB) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Tevogen Bio's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
Tevogen Bio	N/A	N/A	-472.77%

Chemomab Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market.

46.1% of Chemomab Therapeutics shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by company insiders. Comparatively, 70.5% of Tevogen Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Tevogen Bio had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 1 mentions for Tevogen Bio and 0 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 0.71 beat Tevogen Bio's score of 0.67 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Chemomab Therapeutics	Positive
Tevogen Bio	Positive

Tevogen Bio is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

Chemomab Therapeutics presently has a consensus price target of $25.00, suggesting a potential upside of 1,001.32%. Tevogen Bio has a consensus price target of $100.00, suggesting a potential upside of 1,633.10%. Given Tevogen Bio's higher possible upside, analysts plainly believe Tevogen Bio is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Chemomab Therapeutics beats Tevogen Bio on 9 of the 13 factors compared between the two stocks.

How does Chemomab Therapeutics compare to RenovoRx?

RenovoRx (NASDAQ:RNXT) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

3.1% of RenovoRx shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 9.4% of RenovoRx shares are held by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

RenovoRx presently has a consensus price target of $8.50, suggesting a potential upside of 823.81%. Chemomab Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 1,001.32%. Given Chemomab Therapeutics' higher possible upside, analysts plainly believe Chemomab Therapeutics is more favorable than RenovoRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Chemomab Therapeutics has lower revenue, but higher earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	37.01	-$11.17M	-$0.33	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

Chemomab Therapeutics has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Chemomab Therapeutics' return on equity of -89.03% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
Chemomab Therapeutics	N/A	-89.03%	-79.68%

RenovoRx has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

In the previous week, RenovoRx had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 1 mentions for RenovoRx and 0 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 0.71 beat RenovoRx's score of 0.00 indicating that Chemomab Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
RenovoRx	Neutral
Chemomab Therapeutics	Positive

Summary

Chemomab Therapeutics beats RenovoRx on 9 of the 16 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Estrella Immunopharma?

Chemomab Therapeutics (NASDAQ:CMMB) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Chemomab Therapeutics has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Chemomab Therapeutics currently has a consensus target price of $25.00, indicating a potential upside of 1,001.32%. Estrella Immunopharma has a consensus target price of $8.00, indicating a potential upside of 714.25%. Given Chemomab Therapeutics' higher possible upside, research analysts plainly believe Chemomab Therapeutics is more favorable than Estrella Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Estrella Immunopharma had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for Chemomab Therapeutics. Estrella Immunopharma's average media sentiment score of 0.76 beat Chemomab Therapeutics' score of 0.71 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Chemomab Therapeutics	Positive
Estrella Immunopharma	Positive

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

Estrella Immunopharma's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
Estrella Immunopharma	N/A	N/A	-397.36%

46.1% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Chemomab Therapeutics beats Estrella Immunopharma on 6 of the 11 factors compared between the two stocks.

How does Chemomab Therapeutics compare to BioXcel Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are owned by institutional investors. 3.7% of BioXcel Therapeutics shares are owned by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Chemomab Therapeutics has lower revenue, but higher earnings than BioXcel Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	66.59	-$69.90M	-$5.75	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

BioXcel Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 697.10%. Chemomab Therapeutics has a consensus target price of $25.00, indicating a potential upside of 1,001.32%. Given Chemomab Therapeutics' higher possible upside, analysts plainly believe Chemomab Therapeutics is more favorable than BioXcel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Chemomab Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
Chemomab Therapeutics	N/A	-89.03%	-79.68%

In the previous week, Chemomab Therapeutics' average media sentiment score of 0.71 beat BioXcel Therapeutics' score of 0.00 indicating that Chemomab Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
BioXcel Therapeutics	Neutral
Chemomab Therapeutics	Positive

BioXcel Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

Summary

Chemomab Therapeutics beats BioXcel Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Chemomab Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMMB vs. The Competition

Export

Metric	Chemomab Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.34M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-1.02	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	1.14	8.66	10.96	6.46
Net Income	-$8.99M	$23.81M	$3.57B	$337.01M
7 Day Performance	42.77%	3.39%	2.12%	1.69%
1 Month Performance	28.25%	10.81%	5.25%	3.81%
1 Year Performance	-51.91%	62.61%	33.29%	23.90%

Chemomab Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMMB Chemomab Therapeutics	2.1155 of 5 stars	$2.27 flat	$25.00 +1,001.3%	-51.9%	$16.34M	N/A	N/A	20	Gap Down High Trading Volume
ELUT Elutia	3.1961 of 5 stars	$1.03 +3.0%	$6.00 +482.5%	-55.7%	$42.78M	$12.29M	1.20	180	Short Interest Decrease Gap Up
TVGN Tevogen Bio	1.9459 of 5 stars	$9.51 -3.2%	$100.00 +951.5%	-90.7%	$41.12M	N/A	N/A	3	Positive News
RNXT RenovoRx	3.9913 of 5 stars	$0.91 +0.1%	$8.50 +833.3%	-31.8%	$41.05M	$1.12M	N/A	6	Gap Up
ESLA Estrella Immunopharma	2.2907 of 5 stars	$1.00 +7.1%	$8.00 +700.0%	+6.3%	$40.20M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMMB) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemomab Therapeutics (CMMB) Competitors

CMMB vs. ELUT, TVGN, RNXT, ESLA, and BTAI

How does Chemomab Therapeutics compare to Elutia?

Summary

How does Chemomab Therapeutics compare to Tevogen Bio?

Summary

How does Chemomab Therapeutics compare to RenovoRx?

Summary

How does Chemomab Therapeutics compare to Estrella Immunopharma?

Summary

How does Chemomab Therapeutics compare to BioXcel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB vs. The Competition

Chemomab Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Chemomab Therapeutics (CMMB) Competitors

CMMB vs. ELUT, TVGN, RNXT, ESLA, and BTAI

How does Chemomab Therapeutics compare to Elutia?

Do analysts recommend CMMB or ELUT?

Which has more risk and volatility, CMMB or ELUT?

Is CMMB or ELUT more profitable?

Which has stronger earnings and valuation, CMMB or ELUT?

Do institutionals & insiders believe in CMMB or ELUT?

Does the media prefer CMMB or ELUT?

Summary

How does Chemomab Therapeutics compare to Tevogen Bio?

Is CMMB or TVGN more profitable?

Which has more volatility and risk, CMMB or TVGN?

Do insiders & institutionals have more ownership in CMMB or TVGN?

Does the media refer more to CMMB or TVGN?

Which has preferable earnings & valuation, CMMB or TVGN?

Do analysts recommend CMMB or TVGN?

Summary

How does Chemomab Therapeutics compare to RenovoRx?

Do institutionals & insiders hold more shares of RNXT or CMMB?

Do analysts rate RNXT or CMMB?

Which has stronger valuation & earnings, RNXT or CMMB?

Is RNXT or CMMB more profitable?

Which has more risk & volatility, RNXT or CMMB?

Does the media refer more to RNXT or CMMB?

Summary

How does Chemomab Therapeutics compare to Estrella Immunopharma?

Which has more risk & volatility, CMMB or ESLA?

Do analysts rate CMMB or ESLA?

Does the media refer more to CMMB or ESLA?

Which has stronger earnings & valuation, CMMB or ESLA?

Is CMMB or ESLA more profitable?

Do institutionals & insiders hold more shares of CMMB or ESLA?

Summary

How does Chemomab Therapeutics compare to BioXcel Therapeutics?

Do insiders and institutionals believe in BTAI or CMMB?

Which has preferable valuation & earnings, BTAI or CMMB?

Do analysts prefer BTAI or CMMB?

Is BTAI or CMMB more profitable?

Does the media prefer BTAI or CMMB?

Which has more risk & volatility, BTAI or CMMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB vs. The Competition

Chemomab Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools